Dr. Reddy's Laboratories
RDY
#1702
Rank
C$16.50 B
Marketcap
C$19.73
Share price
0.07%
Change (1 day)
-0.65%
Change (1 year)

P/E ratio for Dr. Reddy's Laboratories (RDY)

P/E ratio as of December 2025 (TTM): 17.4

According to Dr. Reddy's Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.3606. At the end of 2024 the company had a P/E ratio of 25.2.

P/E ratio history for Dr. Reddy's Laboratories from 2002 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202425.27.74%
202323.425.86%
202218.6-32.02%
202127.3-30.88%
202039.545%
201927.317.18%
201823.3-38.32%
201737.7-22.25%
201648.5154.15%
201519.1-13.34%
201422.031.22%
201316.8-9.4%
201218.5

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Pfizer
PFE
14.9-13.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
45.1 159.76%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
GlaxoSmithKline
GSK
13.5-22.20%๐Ÿ‡ฌ๐Ÿ‡ง UK
Novartis
NVS
18.0 3.64%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
13.2-23.99%๐Ÿ‡ซ๐Ÿ‡ท France

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.